Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meloxicam and Arthrocentesis for TMJ Internal Derangement
NCT07743684Active, not recruiting
- Start
- Jan 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Randomised trial of meloxicam in temporomandibular joint internal derangement (TMJID) (2 arms). Primary endpoints: Maximum Mouth Opening at 12 weeks, Pain intensity at 12 weeks and 1 more. Started Jan 2026; status: active, not recruiting.
02
Drugs
meloxicam
03
Conditions
temporomandibular joint internal derangement (TMJID)
Beyond the preview
Go deeper on NCT07743684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743684.